Internal restructuring
Border; Midland and Western; West
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

320 jobs
Number of planned job losses
Job loss
Announcement Date
2 November 2004
Employment effect (start)
Foreseen end date
31 August 2005


The 320 job losses at Allergan - a one third cut in the workforce - did not come as a surprise locally as redundancies had been flagged for some time due to the sale of the company's medical device business to Advanced Medical Optics (AMO) in January 2002. The contact lens solutions market has been deregulated in recent years, which means it has become more of a commodity, low-margin, product. All remaining work at the plant will be in high value-added pharmaceuticals. Talks on redundancy terms have commenced between management and trade union representatives. Severance settlements in the pharmaceutical industry tend to be at the higher end of the spectrum.


  • 4 November 2004: Industrial relations news
  • 2 November 2004: The Irish Times


Eurofound (2004), Allergan, Internal restructuring in Ireland, factsheet number 60720, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/60720.